Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

Faculty of 1000 evaluation for Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718018463.793480272 ◽

2013 ◽

Author(s):

Sandra Nuyts

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Randomised Trial ◽

Open Label ◽

Phase 3 ◽

Faculty Opinions recommendation of Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718018463.793481234 ◽

2013 ◽

Author(s):

Bruce Brockstein ◽

Nicholas Campbell

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Randomised Trial ◽

Open Label ◽

Phase 3 ◽

Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108)

European Journal of Cancer ◽

10.1016/j.ejca.2019.08.018 ◽

2019 ◽

Vol 122 ◽

pp. 53-60 ◽

Cited By ~ 2

Author(s):

K. Klinghammer ◽

T. Gauler ◽

A. Dietz ◽

V. Grünwald ◽

J. Stöhlmacher ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Randomised Trial ◽

Open Label ◽

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

The Lancet ◽

10.1016/s0140-6736(19)32591-7 ◽

2019 ◽

Vol 394 (10212) ◽

pp. 1915-1928 ◽

Cited By ~ 230

Author(s):

Barbara Burtness ◽

Kevin J Harrington ◽

Richard Greil ◽

Denis Soulières ◽

Makoto Tahara ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Open Label ◽

Phase 3 ◽

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

The Lancet ◽

10.1016/s0140-6736(18)31999-8 ◽

2019 ◽

Vol 393 (10167) ◽

pp. 156-167 ◽

Cited By ~ 315

Author(s):

Ezra E W Cohen ◽

Denis Soulières ◽

Christophe Le Tourneau ◽

José Dinis ◽

Lisa Licitra ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Open Label ◽

Phase 3 ◽

Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-18-1539 ◽

2018 ◽

Vol 25 (2) ◽

pp. 487-495 ◽

Cited By ~ 4

Author(s):

Magnus T. Dillon ◽

Lorna Grove ◽

Kate L. Newbold ◽

Heather Shaw ◽

Nicholas F. Brown ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Open Label ◽

Phase Ib ◽

Metastatic Squamous Cell Carcinoma

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(11)70034-1 ◽

2011 ◽

Vol 12 (4) ◽

pp. 333-343 ◽

Cited By ~ 165

Author(s):

Jean-Pascal Machiels ◽

Somasundaram Subramanian ◽

Agnes Ruzsa ◽

Gabor Repassy ◽

Igor Lifirenko ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Supportive Care ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Best Supportive Care ◽

Open Label ◽

Phase 3 ◽

Platinum Based Chemotherapy ◽

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)70124-5 ◽

2015 ◽

Vol 16 (5) ◽

pp. 583-594 ◽

Cited By ~ 239

Author(s):

Jean-Pascal H Machiels ◽

Robert I Haddad ◽

Jérôme Fayette ◽

Lisa F Licitra ◽

Makoto Tahara ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

Second Line ◽

Open Label ◽

Phase 3 ◽

Head Neck

A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

Annals of Oncology ◽

10.1093/annonc/mdw376.68 ◽

2016 ◽

Vol 27 ◽

pp. vi350 ◽

Cited By ~ 5

Author(s):

A. Argiris ◽

M. Gillison ◽

R.L. Ferris ◽

K. Harrington ◽

T.K. Sanchez ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Therapy ◽

Line Therapy ◽

Faculty Opinions recommendation of Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736682352.793578124 ◽

2020 ◽

Author(s):

Jaffer Ajani

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Oesophageal Squamous Cell Carcinoma ◽

Open Label ◽

Phase 3 ◽